Malignant Mesothelioma - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 547
Inquire Before Buying

Malignant Mesothelioma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 34, 25, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 6 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Malignant Mesothelioma - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
Introduction 5
Malignant Mesothelioma - Overview 6
Malignant Mesothelioma - Therapeutics Development 7
Malignant Mesothelioma - Therapeutics Assessment 20
Malignant Mesothelioma - Companies Involved in Therapeutics Development 33
Malignant Mesothelioma - Drug Profiles 60
Malignant Mesothelioma - Dormant Projects 521
Malignant Mesothelioma - Discontinued Products 523
Malignant Mesothelioma - Product Development Milestones 524
Appendix 536

List of Tables
Number of Products under Development for Malignant Mesothelioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Malignant Mesothelioma - Pipeline by Aduro BioTech Inc, H2 2017
Malignant Mesothelioma - Pipeline by Advantagene Inc, H2 2017
Malignant Mesothelioma - Pipeline by AnGes MG Inc, H2 2017
Malignant Mesothelioma - Pipeline by arGEN-X BV, H2 2017
Malignant Mesothelioma - Pipeline by ArQule Inc, H2 2017
Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Biogen Inc, H2 2017
Malignant Mesothelioma - Pipeline by Bionomics Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Biotecnol Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H2 2017
Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2017
Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H2 2017
Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H2 2017
Malignant Mesothelioma - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Concordia International Corp, H2 2017
Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2017
Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2017
Malignant Mesothelioma - Pipeline by EpiZyme Inc, H2 2017
Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Five Prime Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Genelux Corp, H2 2017
Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2017
Malignant Mesothelioma - Pipeline by Horizon Pharma Plc, H2 2017
Malignant Mesothelioma - Pipeline by Inventiva, H2 2017
Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Malignant Mesothelioma - Pipeline by MacroGenics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Malignant Mesothelioma - Pipeline by MedImmune LLC, H2 2017
Malignant Mesothelioma - Pipeline by Merck & Co Inc, H2 2017
Malignant Mesothelioma - Pipeline by Merck KGaA, H2 2017
Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by MolMed SpA, H2 2017
Malignant Mesothelioma - Pipeline by Morphotek Inc, H2 2017
Malignant Mesothelioma - Pipeline by MTG Biotherapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Novartis AG, H2 2017
Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Malignant Mesothelioma - Pipeline by OSE Immunotherapeutics, H2 2017
Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2017
Malignant Mesothelioma - Pipeline by Pharma Mar SA, H2 2017
Malignant Mesothelioma - Pipeline by Philogen SpA, H2 2017
Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Seattle Genetics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Selecta Biosciences Inc, H2 2017
Malignant Mesothelioma - Pipeline by Sorrento Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Targovax ASA, H2 2017
Malignant Mesothelioma - Pipeline by Tesaro Inc, H2 2017
Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by TREAT U SA, H2 2017
Malignant Mesothelioma - Pipeline by UbiVac LLC, H2 2017
Malignant Mesothelioma - Pipeline by VasGene Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Verastem Inc, H2 2017
Malignant Mesothelioma - Pipeline by Vyriad Inc, H2 2017
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co Ltd, H2 2017
Malignant Mesothelioma - Dormant Projects, H2 2017
Malignant Mesothelioma - Dormant Projects, H2 2017 (Contd..1), H2 2017
Malignant Mesothelioma - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Malignant Mesothelioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • Kaposi Sarcoma - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 140
    Kaposi Sarcoma - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H2 2017, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape. Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usua......
  • Global Circulating Tumor Cells Market Research Report 2017
    Published: 10-Nov-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Circulating Tumor Cells in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Biliary Tumor - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Biliary Tumor. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Biliary Tumor which can turn out to b......
  • Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Chemotherapy Induced Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Chemotherapy Induced Anemia. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Chemother......
  • Larynx Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Larynx Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Larynx Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Larynx Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Larynx ......
  • Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Hodgkin's lymphoma (HL) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagno......
  • Lip and Oral Cavity Cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Lip and Oral Cavity Cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Lip and Oral Cavity Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Lip and Oral Cavity Cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet m......
  • Liver cancer -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Liver cancer - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Liver cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Liver cancer prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Liver cancer.......
  • Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Small Cell Lung Cancer for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Small Cell Lung Cancer . It enables unde......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs